Genmab A/S : Investor Presentation - May 2024

Rooted in Science, Inspired by Patients

Investor Presentation

May 2024

Forward looking statement

This presentation contains forward looking statements. The words "believe", "expect", "anticipate", "intend" and "plan" and similar expressions identify forward looking statements. All statements other than statements of historical facts included in this presentation, including, without limitation, those regarding our financial position, business strategy, plans and objectives of management for future operations (including development plans and objectives relating

to our products), are forward looking statements. Such forward looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward looking statements. Such forward looking statements are based on numerous assumptions regarding our present and future business strategies and the environment in which we will operate in the future. The important factors that could cause our actual results, performance or achievements to differ materially from those in the forward looking statements include, among others, risks associated with product discovery and

development, uncertainties related to the outcome of clinical trials, slower than expected rates of patient recruitment, unforeseen safety issues resulting from the administration of our products in patients, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products obsolete, and other factors. Further, certain forward looking statements are based upon assumptions of future events which may not prove to be accurate. The forward looking statements in this document speak only as at the date of this presentation. Genmab does not undertake any obligation to update or revise forward looking statements in this presentation nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law.

© Genmab 2024

2

For Investor audience only. Not for public information or use. Not for promotional use.

Towards 2030:

Evolving Into a Fully

Integrated Biotech

Innovation Powerhouse

Core Purpose

Our unstoppable team will improve the lives of patients through innovative and differentiated antibody therapeutics.

Our Strategy

• Focus on core competence
• Turn science into medicine
• Build a profitable & successful biotech

Vision

By 2030, our KYSO® antibody medicines are fundamentally transforming the lives of people with cancer and other serious diseases.

© Genmab 2024

3

For Investor audience only. Not for public information or use. Not for promotional use.

Solid Track Record and

Financial Foundation

Fuel Our Growth

• Over 40 cumulative INDs since 1999
• Innovative clinical pipeline: 10 Genmab owned ≥50%
• 8 approved medicines based on Genmab's innovation and antibody expertise
• Two approved medicines:
  Tivdak® (tisotumab vedotin-tftv) and EPKINLY®/TEPKINLY® (epcoritamab)

• Growing recurring revenue
• Sustainably profitable with cash position of ~USD 4.2B
• Investing in our capabilities
• Experienced, international leadership team

© Genmab 2024

4

Tivdak is being co-developed and co-promoted by Genmab and Pfizer. EPKINLY is being co-developed and co-promoted by Genmab and AbbVie

For Investor audience only. Not for public information or use. Not for promotional use.

The Genmab Model

Deep insight into antibody biology & disease targets

Match in-house expertise with strategic collaborations & partnerships

Proprietary technologies enable us to build a world-class pipeline

Strong pipeline of potential 1st-in-class /best-in-class products

© Genmab 2024

5

For Investor audience only. Not for public information or use. Not for promotional use.

Innovative Clinical Pipeline: Genmab Proprietary* and Partnered Products - Most Advanced Development Phase

Early Clinical	Phase 2	Phase 3	Approved‡
Development

	GEN1053 (HexaBody®-CD27, BNT313)1	Acasunlimab (GEN1046/BNT311, DuoBody-	Epcoritamab (EPKINLY)3
Genmab	GEN1059 (DuoBody®-EpCAMx4-1BB,	PD-L1x4-1BB)1	Tisotumab vedotin (Tivdak)4
owned	BNT314) 1	GEN1042 (DuoBody-CD40x4-1BB, BNT312)1
products	GEN1056 (BNT322)1	GEN3014 (HexaBody-CD38)2
≥50%	GEN3017 (DuoBody-CD3xCD30)	GEN1047 (DuoBody-CD3xB7H4)

≥Ph 2	Additional early-stage	Ordesekimab5	Inclacumab8	Daratumumab (DARZALEX®)7
Products	programs in	6	Mim89	Amivantamab (RYBREVANT®)7
owned by 3rd
development	Lu AF82422
party, created				Teclistamab (TECVAYLI®)7
by Genmab or				Talquetamab (TALVEY )7
incorporating				Ofatumumab (Kesimpta®)10
Genmab's
			Teprotumumab (TEPEZZA®)11
innovation

*Products where Genmab has ownership of at least 50%

‡See local prescribing information for full indications / safety information

1Co-development with BioNTech; 2Genmab is developing HexaBody-CD38 in an exclusive worldwide license and option agreement with Janssen; 3Co-development with AbbVie; 4Co-development with; Seagen (Pfizer) 5Development by Sanofi;

6Development by Lundbeck; 7Development and/or discovery by Janssen; 8Development by Pfizer (Global Blood Therapeutics); 9Development by Novo Nordisk; 10Development by Novartis; 11Development by Amgen

© Genmab 2024

6

For Investor audience only. Not for public information or use. Not for promotional use.

Power of Discovery and Drug Development Engine

>40

Cumulative

INDs

Approved Products

In Current Clinical

Development

Over 20 in Current Clinical Development or Approved

8 Approved 2 Phase 3

6 Phase 2

1 Phase 1/2

4 Phase 1

8 Product

Approvals

Entered Clinical	Entered Phase 3 /	Approved
Development	Registrational
8	8	8

102

2024 Revenue Guidance:

$2.8bn -$3.0bn

End-Market:$17.5bn*

Genmab Proprietary Pipeline

From 2 in

development in 2017 to 2 approved and

10 in development

Genmab cumulative investments 2017 to 2023 is ~$5bn** of which ~75% in R&D

by 2024

© Genmab 2024

7

*Company Collected Consensus pre 4Q 2023	For Investor audience only. Not for public information or use. Not for promotional use.
**Sum of operating expenses 2017 to 2023 converted at USD/DKK 6.8

World-class R&D Engine

Innovative Technologies Powering Our Pipeline

DuoBody technology

Mix/Other, 29%

HexaBody technology

DuoBody, 47%

DuoHexaBody® technology

HexElect ® technology

HexaBody, 24%

DuoBody

HexaBody

Mix/Other

© Genmab 2024

8

For Investor audience only. Not for public information or use. Not for promotional use.

EPKINLY/TEPKINLY (epcoritamab)

Approved in the U.S., Europe and Japan

Approved in U.S., Europe, Japan and other territories1

• First bispecific antibody in U.S. to treat adults with R/R DLBCL1
• First and only SC bispecific antibody in Europe to treat adults with R/R DLBCL1
• First and only bispecific antibody in Japan to treat adults with certain types of R/R LBCL1

Bispecific antibody delivered as off the shelf, rapid, SC injection, studied in B- NHL2,3

Mechanism of Action

1. See local prescribing information for full indication and safety information. U.S. FDA accelerated approval; continued approval may be contingent on verification and confirmation of clinical benefit in a confirmatory trial(s). 2. Engelberts PJ, et al. EBioMedicine. 2020;52:102625. 3. van der Horst HJ, et al. Blood Cancer J. 2021;11:38. TCR, T-cell receptor.

© Genmab 2024

9

For Investor audience only. Not for public information or use. Not for promotional use.

Broad & Comprehensive Epcoritamab Development Plan

B-NHL Type			Intervention	Most Advanced Phase
Front-line
DLBCL		Epcoritamab + R-CHOP	Phase 3
	Anthracycline ineligible elderly patients	Epcoritamab +/- lenalidomide	Phase 2
		Epcoritamab + pola-R-CHP	Phase 1b/2
FL			Epcoritamab + R2	Phase 3
			Epcoritamab + BR	Phase 1b/2
Relapsed or refractory
DLBCL	ASCT ineligible patients		Epcoritamab + lenalidomide	Phase 3
			Epcoritamab vs SOC	Phase 3
		Epcoritamab + lenalidomide	Phase 1b/2
		Epcoritamab + lenalidomide + ibrutinib	Phase 1b/2
	ASCT eligible patients	Epcoritamab + R-DHAX/C	Phase 1b/2
	ASCT eligible patients	Epcoritamab + R-ICE	Phase 1b/2
	ASCT eligible patients		Epcoritamab + Salvage	Phase 3
			Epcoritamab + GemOx	Phase 1b/2
FL		Epcoritamab + R2	Phase 3
		Epcoritamab + lenalidomide	Phase 1b/2
DLBCL & FL	Outpatient	Epcoritamab monotherapy	Phase 2
B-NHL	DLBCL, FL, MCL	Epcoritamab monotherapy	Phase 2
	Japanese patients	Epcoritamab monotherapy	Phase 1/2
	Pediatric patients	Epcoritamab monotherapy	Phase 1
	Chinese patients	Epcoritamab monotherapy and + SOC	Phase 1
CLL	CLL	Epcoritamab + venetoclax	Phase 2*
	Chemo-ineligible frontline & R/R Richter's Syndrome	Epcoritamab monotherapy	Phase 1b/2
	Chemo-eligible frontline & R/R Richter's Syndrome	Epcoritamab + R-CHOP	Phase 1b/2
	Chemo-ineligible Richter's Syndrome	Epcoritamab + lenalidomide	Phase 1b/2
		Epcoritamab monotherapy	Phase 1b/2
	Double-exposed CLL
		Epcoritamab + venetoclax	Phase 1b/2
	CLL

B-NHL:B-cellNon-Hodgkin Lymphoma; BR: bendamustine + rituximab; DLBCL: diffuse large B-cell lymphoma; FL: follicular lymphoma; MCL: mantle cell lymphoma; SOC: standard of care; R2 = Revlimid + rituximab: pola-R-CHP: polatuzumab vedotin, rituximab, cyclophosphamide, HCL, prednisone; R-ICE = rituximab, ifosfamide, carboplatin, and etoposide phosphate

*Trial sponsored by Stichting Hemato-Oncologie voor Volwassenen Nederland (HOVON)

For Investor audience only. Not for public information or use. Not for promotional use.